In this section:

14 January 2019

Xeljanz (Tofacitinib) - New Psoriatic Arthritis Treatment Approved for Use in Scotland

The SMC approves Xeljanz (Tofacitinib) for the treatment of psoriatic arthritis in adults in Scotland.

The Scottish Medicines Consortium (SMC) has today published its decision to recommend Xeljanz (Tofacitinib) as a treatment for adults with psoriatic arthritis in Scotland. This brings Scotland in line with England and Wales where the National Institute for Health and Care Excellence (NICE) approved Xeljanz for the treatment of psoriatic arthritis in October 2018.

In Scotland, Xeljanz is recommended to treat psoriatic arthritis, in combination with methotrexate, where the condition has not responded adequately to at least two standard disease-modifying antirheumatic drugs (DMARDs) given either alone or in combination. 

How does Xeljanz work?

Xeljanz, which is taken by tablet, works differently to any of the other treatments that are currently available for psoriatic arthritis. It belongs to a class of medications known as JAK inhibitors and works by blocking the actions of a group of proteins called Janus Kinases (JAKs) which are involved in causing the inflammation in psoriatic arthritis. By blocking their actions, Xeljanz reduces the inflammation and other symptoms of psoriatic arthritis.

You can read more about Xeljanz, as well as its dosing regime and possible side effects by downloading our information sheet.

The Psoriasis Association is the UK's leading national charity and membership organisation for people affected by psoriasis – patients, families, carers and health professionals Read More >

Get in touch

The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF


Tel :
01604 251 620
Registered with Fundraising Regulator -

© The Psoriasis Association Charitable Incorporated Organisation Number: 1180666 Scotland: SC039886 Privacy PolicyCookies

Site by Spoken Image | glitterfish

We use cookies to help us provide you with a better service, but do not track anything that can be used to personally identify you.

If you prefer us not to set these cookies, please visit our Cookie Settings page or continue browsing our site to accept them.